All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
What has the SAMBA trial taught us about the treatment of elderly high-risk AML/MDS patients?
Bookmark this article
During the 2020 Annual Meeting of the Society of Hematologic Oncology (SOHO), the AML Hub spoke to Uwe Platzbecker, University of Leipzig Medical Center, Leipzig, DE, about the SAMBA trial, and what impact the results will have on how we treat elderly high-risk patients with AML/MDS.
What has the SAMBA trial taught us about the treatment of elderly high-risk AML/MDS patients?
Patients with hypomethylating agent-refractory AML/MDS have very limited treatment options. The SAMBA trial aimed to address this unmet clinical need, and evaluated the safety and efficacy of single-agent talacotuzumab, a CD123-directed monoclonal antibody, in this setting.
Talacotuzumab was not well tolerated and showed limited efficacy in elderly high-risk patients with AML/MDS. In a parallel phase III study evaluating talacotuzumab + decitabine vs decitabine alone, the combination did not demonstrate superiority over single-agent decitabine.
More about...
Newsletter
Subscribe to get the best content related to AML delivered to your inbox